Characteristics of “super responders” and “super nonresponders” to first biologic monotherapy for psoriasis: a nested case-control study
BJD, 2023.
Kayleigh J. Mason, Oras A. Alabas, Nick Dand, Richard B. Warren, Nick J. Reynolds, Jonathan N.W.N. Barker, Zenas Z. N. Yiu, Catherine H. Smith, Christopher E.M. Griffiths, the BADBIR Study Group.
Read publication: BJD
Related
Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Sec...
Risks of basal cell and squamous cell carcinoma in psoriasis patients after treatment with biologic ...
Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective c...
0 Comments